A Novel Mechanism for Sarcopenia in Chronic Kidney Disease

慢性肾脏病肌肉减少症的新机制

基本信息

项目摘要

Sarcopenia (muscle wasting) is a crippling condition that affects 25% of the aging population and even a greater percentage of subjects with chronic kidney disease (CKD), and is disproportionately high among veterans. Now recognized as a disease entity with its own ICD-10 code, it is associated with increased mortality and carries an annual US cost estimated to be more than 11.8 billion dollars and yet there is very little known of its pathogenesis or treatment. Sarcopenia is common in the aging population, especially those with obesity and diabetes. However, one population that commonly suffers from sarcopenia are those individuals suffering from chronic kidney disease, where both young and old are affected. It is now recognized that the disease does not result simply from poor nutrition and physical inactivity, but is often driven by inflammation and oxidative stress that can progress to protein-energy wasting, frailty and cachexia. The biological processes that are involved include effects of metabolic acidosis to stimulate protein catabolism from activation of the ubiquitin system, overexpression of myostatin that inhibits muscle growth, effects of insulin resistance, and other mechanisms. While much has been learned about these basic cellular processes involved in sarcopenia, here we present a novel hypothesis suggesting that the enzyme AMP deaminase 1 (AMPD1) may have a central role in causing sarcopenia by both regulating intracellular energy (ATP) levels and driving inflammation and oxidative stress. Using a model of chronic kidney disease in mice (remnant kidney model on a high protein diet), we have documented that the animals develop sarcopenia and in preliminary studies that sarcopenia does not occur in mice lacking AMPD1 with equivalent kidney damage. Here we will extend our studies to determine the effect of blocking AMPD1 in both male and female and both young and old mice with kidney disease, in association with extensive phenotyping including exercise tolerance, and studies of energy balance and body composition. Second we will explore the mechanisms by which AMPD1 activation causes inflammation, focusing on the role of uric acid and inhibition of AMP activated protein kinase. Finally, we will explore the basis underlying the activation of AMPD1 in chronic kidney disease, with an emphasis on the role of intracellular phosphate depletion and insulin resistance. If we identify activation of AMPD1 as a cause of sarcopenia and show that it is driven by insulin resistance, intracellular phosphate depletion and uric acid generation, we will not only identify a mechanism driving a severe complication of chronic kidney disease but also a potential way to intervene both prophylactically and therapeutically. Such a discovery would be of great help to all individuals with chronic kidney disease, and would have a big impact on Veterans and the Veteran Health Administration.
肌肉减少症(肌肉萎缩)是一种致残性疾病,影响着25%的老年人口,甚至是老年人

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard Joseph Johnson其他文献

Richard Joseph Johnson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard Joseph Johnson', 18)}}的其他基金

Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
  • 批准号:
    10221502
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
  • 批准号:
    10441315
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
  • 批准号:
    10659119
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
A Novel Mechanism for Sarcopenia in Chronic Kidney Disease
慢性肾脏病肌肉减少症的新机制
  • 批准号:
    10454871
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
  • 批准号:
    10022080
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Dietary Salt has an Unrecognized Role in Modulating Energy Intake and Metabolic Syndrome
膳食盐在调节能量摄入和代谢综合征方面的作用尚未被认识
  • 批准号:
    9114329
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity
果糖激酶抑制治疗肥胖的科学价值和可行性
  • 批准号:
    9464351
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
果糖激酶与非糖尿病和衰老相关的慢性肾脏病
  • 批准号:
    9275427
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
果糖激酶与非糖尿病和衰老相关的慢性肾脏病
  • 批准号:
    8966551
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
果糖激酶与非糖尿病和衰老相关的慢性肾脏病
  • 批准号:
    9789159
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Late-Stage Functionalisation of Cyclic Guanosine Monophosphate - Adenosine Monophosphate
环单磷酸鸟苷-单磷酸腺苷的后期功能化
  • 批准号:
    2751533
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Studentship
The Role of Chronic Pharmacological Adenosine Monophosphate-Activated Protein Kinase Activation at the Neuromuscular Junction
慢性药理学单磷酸腺苷激活蛋白激酶激活在神经肌肉接头处的作用
  • 批准号:
    575833-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Targeting adenosine monophosphate activated protein kinase (AMPK) to reduce cocaine relapse
靶向单磷酸腺苷激活蛋白激酶 (AMPK) 减少可卡因复吸
  • 批准号:
    10593045
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Targeting adenosine monophosphate activated protein kinase (AMPK) to reduce cocaine relapse
靶向单磷酸腺苷激活蛋白激酶 (AMPK) 减少可卡因复吸
  • 批准号:
    10303255
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
The regulation of electrical coupling between neuroendocrine cells by cyclic adenosine monophosphate and protein kinase A
环磷酸腺苷与蛋白激酶A对神经内分泌细胞电耦合的调节
  • 批准号:
    565217-2021
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Dissecting the Molecular Mechanisms of the Histone Acetyltransferase/Cyclic Adenosine Monophosphate Binding Protein Interactome Using Protein-Observed Fluorine NMR
使用蛋白质观察的氟 NMR 剖析组蛋白乙酰转移酶/环单磷酸腺苷结合蛋白相互作用组的分子机制
  • 批准号:
    1904071
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Osmotic stress regulation and the role of cyclic di-adenosine monophosphate (c-di-AMP) in Staphylococcus aureus
金黄色葡萄球菌的渗透应激调节和环二腺苷单磷酸 (c-di-AMP) 的作用
  • 批准号:
    318765828
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Research Fellowships
Novel mechanisms controlling signaling by adenosine monophosphate-activated protein kinase, central regulator of energy homeostasis
通过单磷酸腺苷激活蛋白激酶控制信号传导的新机制,能量稳态的中央调节器
  • 批准号:
    FT130100988
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
    ARC Future Fellowships
The roles of cyclic adenosine monophosphate (cAMP) in suppressive functions of regulatory T cells
环磷酸腺苷 (cAMP) 在调节性 T 细胞抑制功能中的作用
  • 批准号:
    25893115
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Molecular mechanisms of cyclic Adenosine Monophosphate (AMP) induced apoptosis
环磷酸腺苷(AMP)诱导细胞凋亡的分子机制
  • 批准号:
    DP110100417
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
    Discovery Projects
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了